Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 16

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 16
---
2 proof of concept clinical trial for treatment of basal cell carcinoma using our doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use any net proceeds to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin diseases. We will use any remaining proceeds from sales under the SEPA for general corporate purposes and working capital. See "Use of Proceeds." |
| Voting rights                                 | Each outstanding common share will be entitled to one vote on all matters submitted to a vote of shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Listing                                       | Our common shares are listed on the Nasdaq under the symbol "MDCX".                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dividend policy                               | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors.                                                                                                                                                                                                                                                                                                                         |
| Risk factors                                  | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

Except as otherwise noted, all information contained in this prospectus assumes no exercise of our outstanding options (as described herein) or warrants. The number of common shares that will be outstanding after this offering is based on 13,572,737 common shares outstanding as of May 21, 2025.

<div align='center'>- 6 -

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus

We have derived the selected consolidated statement of operations for the three months ended March 31, 2025 and 2024 and the selected consolidated balance sheet information as of March 31, 2025 and December 31, 2024 from our interim unaudited consolidated financial statements and audited consolidated financial statements,